What Braveheart Bio does

Braveheart Bio, Inc. is a clinical-stage biotechnology company headquartered in San Francisco that is developing BHB-1893 (also known as HRS-1893), a selective, reversible, small-molecule cardiac myosin inhibitor intended to treat hypertrophic cardiomyopathy (HCM), including both obstructive (oHCM) and non-obstructive (nHCM) forms. The asset was discovered and initially developed by Jiangsu Hengrui Pharmaceuticals and licensed worldwide (excluding Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) to Braveheart in September 2025 for a $65 million upfront payment plus development and commercial milestones and royalties, with total potential deal value of up to approximately $1.013 billion. BHB-1893 is designed to modulate cardiac myosin activity, reducing hypercontractility while preserving left ventricular ejection fraction (LVEF), and has demonstrated a shallow EF exposure-response curve, simplified dosing with minimal titration, and positive Phase 2 results in both oHCM (42 patients, March 2026) and nHCM (84 patients, May 2026), with global pivotal Phase 3 development planned for 2026.

The company is pre-commercial and pre-revenue, with no approved products on the market. Braveheart launched publicly on November 5, 2025 alongside a $185 million Series A financing led by Andreessen Horowitz (a16z Bio + Health), Forbion, and OrbiMed, with participation from Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Its business model is therefore a venture-backed drug development model with future revenue expected to come from commercialization (or out-licensing) of BHB-1893 in the licensed ex-China territories through specialty cardiology channels, contingent on regulatory approval. Target customers are cardiologists and specialty HCM centers serving an HCM population of approximately 1 in 500 individuals in the United States (~700,000), of whom fewer than 20% of eligible oHCM patients currently receive targeted therapy. Leadership includes CEO Travis Murdoch (ex-HI-Bio/Biogen), CDO Michele Anderson (ex-Gilead/Biogen), CMO Emil deGoma (ex-Tourmaline Bio/Akebia), CSO Marc Evanchik (ex-MyoKardia/Edgewise, key contributor to Camzyos), and CFO Paul Rickey (Alpine Immune Sciences, acquired by Vertex), with Chris Viehbacher (former Biogen CEO) as Board Chair.

Name

Braveheart Bio

Legal name

Braveheart Bio, Inc.

Website

https://braveheart.bio

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893, a selective cardiac myosin inhibitor in-licensed from Hengrui Pharma for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, backed by a $185 million Series A from top-tier biotech investors.

Ownership category

akta.pro rank

Product category

Cardiovascular Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

Keywords

• Cardiac myosin inhibitor
• Hypertrophic cardiomyopathy therapy
• Precision cardiovascular drug
• Rare disease biopharmaceutical
• Clinical-stage biotechnology

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Licensing & milestone payments (in-licensed asset): Braveheart Bio is pre-commercial / pre-revenue. The company has not yet generated product revenue; its development is funded by venture capital plus in-licensed program economics. Per the September 2025 exclusive worldwide license (ex-Mainland China, Hong Kong SAR, Macao SAR, Taiwan Region) with Jiangsu Hengrui Pharma for HRS-1893, Braveheart paid a $65 million upfront and is obligated to pay development/commercial milestones plus royalties on sales. Hengrui is eligible for up to ~$1.013 billion in total deal value plus royalties.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893 (also known as HRS-1893), a selective, reversible, small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) in both its obstructive (oHCM) and non-obstructive (nHCM) forms. The asset was in-licensed from Jiangsu Hengrui Pharma under an exclusive worldwide license (excluding Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) and is being advanced through global late-stage clinical development, with planned global pivotal Phase 3 trials in 2026.

Product overview

Braveheart Bio's product offering is centered on a single investigational drug candidate — BHB-1893 (also referred to as HRS-1893, the designation used by originator Jiangsu Hengrui Pharma). There is no broader platform-plus-modules architecture; the company's portfolio revolves around advancing this one selective, small-molecule cardiac myosin inhibitor through global late-stage clinical development for hypertrophic cardiomyopathy (HCM). BHB-1893 and HRS-1893 refer to the same molecule (Braveheart Bio's development name and Hengrui's originator designation), being progressed in parallel Phase 2/3 programs for both the obstructive (oHCM) and non-obstructive (nHCM) forms of HCM under an exclusive worldwide licensing arrangement with Hengrui Pharma.

Differentiator

Problem solved

Functional benefit

Brands

• BHB-1893: Lead investigational product candidate, a selective, reversible small-molecule cardiac myosin inhibitor (also known as HRS-1893), being developed for hypertrophic cardiomyopathy (obstructive and non-obstructive).

Products and services

• BHB-1893 (also designated HRS-1893) BHB-1893 is a selective, reversible, small-molecule cardiac myosin inhibitor being developed as an investigational next-generation oral therapy for hypertrophic cardiomyopathy. It is engineered for rapid onset of action, minimal impact on left ventricular ejection fraction (LVEF), favorable safety, and simplified dosing with minimal titration. The candidate is being advanced through global Phase 2/3 clinical development for both obstructive (oHCM) and non-obstructive (nHCM) forms of HCM. Positive Phase 2 data have been reported in both oHCM (42 patients, NCT06516068) and nHCM (84 patients, NCT06816251). The molecule is also known as HRS-1893, the designation used by originator Jiangsu Hengrui Pharma.

Quantifiable outcome

• Phase 2 oHCM: Valsalva LVOT-G complete response (<30 mmHg) of up to 86%; LVEF decrease only 1.8%-2.7%; KCCQ-CSS +10.5 points, pVO2 +1.0 mL/kg/min, NT-proBNP -88% in Group 2; 89% of patients well-served at 40 or 60 mg twice daily with minimal to no titration.
• +1 more outcomes

Named customers1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Jiangsu Hengrui Pharma (Hengrui Pharma)flagshipStrategic or Co-development Partner · 1 September 2025Exclusive worldwide licensing agreement (ex-Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) for the development, manufacture and commercialization of HRS-1893 (BHB-1893). $65 million upfront payment, with potential milestones and royalties, and total potential deal value of up to ~$1.013 billion. Hengrui continues to run the ongoing Phase 3 study in oHCM in China (NCT07021976). Braveheart and Hengrui jointly announce Phase 2 results in oHCM (March 30, 2026) and nHCM (May 11, 2026) and continue to co-develop the asset.
• FGS GlobalcoreGTM or Marketing PartnerExternal communications/IR agency serving as Braveheart Bio's media contact ([email protected]) on official press releases including Phase 2 nHCM and oHCM announcements.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Tenaya Therapeutics: Tenaya is developing TN-201, an adeno-associated virus gene therapy targeting MYBPC3 mutations, the most common genetic cause of HCM. It represents an emerging modality (gene therapy) competing in the same HCM patient population with a different mechanism of action.
• Cardurion Pharmaceuticals: Cardurion is a private cardiovascular-focused biotechnology company developing therapies for heart failure and related cardiac diseases, with a capital structure and clinical-development profile broadly comparable to Braveheart. It competes for capital, talent, and specialty cardiology commercial channels in adjacent indications.
• Lexeo Therapeutics: Lexeo is developing cardiac-targeted genetic medicines including LX2000 for Friedreich's ataxia cardiomyopathy and programs in additional genetic cardiomyopathies. It overlaps with Braveheart's HCM focus area via disease-modifying approaches to inherited cardiac muscle disorders.

Direct peers

• Cytokinetics: Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor for obstructive HCM, in late-stage clinical trials (SEQUOIA-HCM Phase 3). It is the closest direct competitor to Braveheart in the cardiac myosin inhibitor class for HCM and competes head-to-head for specialty cardiology market share upon approval.
• Edgewise Therapeutics: Edgewise Therapeutics is developing EDG-7500, a novel cardiac sarcomere modulator for HCM and hypertrophic heart disease, with leadership and scientific staff overlapping the cardiac myosin inhibitor community. It is a smaller, earlier-stage direct competitor pursuing the same disease-modification thesis in HCM.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam markets Onpattro and Amvuttra for transthyretin amyloid cardiomyopathy and has a broader RNAi-based cardiovascular pipeline. It serves as a broader RNA/genetic medicines incumbent operating in cardiology specialty channels with overlapping patient populations (cardiac muscle disease).
• Bristol Myers Squibb: BMS owns Camzyos (mavacamten), the first-in-class cardiac myosin inhibitor approved for oHCM, acquired via the $13.1B MyoKardia deal. Camzyos is the established standard of care Braveheart must differentiate against and provides a direct comparator for efficacy, safety, dosing convenience, and commercial launch benchmarks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/braveheart-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Braveheart Bio